Pharmaceutical Market Europe • November 2022 • 38-40
APPOINTMENTS
Merck
Robert Davis
Merck has appointed Robert Davis as chairman of the board. Davis’ new role will be effective as of 1 December 2022 and he will succeed Kenneth Frazier. Davis currently serves as president and chief executive officer, and became Merck’s president in April 2021. He then went on to become Merck’s chief executive officer and a member of its board in July 2021. He joined the company in 2014 as its chief financial officer. Before joining Merck, he served as corporate vice president and president of Baxter’s Medical Products business. While there, he also served as the company’s renal business, chief financial officer and treasurer. Prior to Baxter, he served in various senior positions spanning 14 years at Eli Lilly.
Bioxodes
Marc Dechamps
Bioxodes has appointed Marc Dechamps as chief executive officer. Dechamps brings over 30 years of management experience in the biotech and pharmaceutical industries. He has previously worked for GSK as an executive director and then in various senior roles for ViiVHealthcare in 2009. In 2016, he founded and became managing director of XMF Consulting, a company supporting biotech businesses.
Evaxion Biotech
Per Norlén
Evaxion Biotech has appointed Per Norlén as chief executive officer. Norlén is a board-certified physician and associate professor who brings more than 20 years' experience in the biotech sector to the role, the last decade of which has been in executive leadership roles. Most recently, Norlén served as chief executive officer at Targinta, a position he held prior to this at Xintela and Alligator Bioscience.
Vico Therapeutics
Scott Schobel
Vico Therapeutics has appointed Scott Schobel as chief medical officer. Schobel offers drug development experience, including as the clinical science leader of the Tominersen programme for Huntington’s disease at Roche. He was assistant professor of clinical psychiatry at Columbia University Medical Center and served as medical director of Columbia University Medical Center’s Center of Prevention and Evaluation.
LifeMine Therapeutics
Martin Stahl
LifeMine Therapeutics has appointed Martin Stahl as chief scientific officer, who will also lead the company’s operations at its European offices in Basel, Switzerland. Stahl joins LifeMine from Roche, where he held a variety of scientific leadership roles over 25 years, including positions in medicinal chemistry, immunology, portfolio management and research technologies.
Abalos Therapeutics
Thomas Bogenrieder
Abalos Therapeutics has appointed Thomas Bogenrieder as chief medical officer. Bogenrieder brings over 17 years' international clinical development experience, most recently serving as chief clinical officer for AMAL Therapeutics. He served as chief medical officer at Evaxion Biotech. Bogenrieder has held roles in oncology and medical affairs at Boehringer Ingelheim and GlaxoSmithKline.
TransCelerate BioPharma
Janice Chang
TransCelerate BioPharma has appointed Janice Chang as chief executive officer. Chang's career spans 30 years, serving as the company’s chief operating officer, having joined in 2014. At TransCelerate, she served as senior vice president of global operations and then in 2018 as the company’s executive vice president. She previously served as Accenture’s management consulting lead.
LifeMine Therapeutics
Louis Plamondon
LifeMine Therapeutics has appointed Louis Plamondon as executive vice president and head of CMC. He was senior vice president and head of CMC at Constellation Pharmaceuticals, where he led pre-development and development activities. He holds a PhD in organic chemistry from the Université de Montréal and completed his postdoctoral fellowship at Harvard University.
Closed Loop Medicine
Simon Ramsden
Closed Loop Medicine has appointed Simon Ramsden as its new chief financial officer. Ramsden joined Closed Loop Medicine after working at EUSA Pharma, where he served as vice president head of global finance. Prior to this, he spent a decade at GSK, most recently as finance director of consumer health R&D, managing global budgets across six international sites.
Atriva Therapeutics
Tim Overend
Atriva Therapeutics has appointed Tim Overend as vice president, clinical development and regulatory. Prior to joining Atriva Therapeutics, in 2018, Overend served as the executive regulatory scientific director at AstraZeneca. Before his role at AstraZeneca, he served at Mundipharma, starting at the company as its principal medical scientific expert, and then moving into the position as the head of clinical development, respiratory. Between 1997 and 2014, he worked as a senior clinical scientist and principal medical scientific expert at Novartis, overseeing phase 2/3 clinical development plans, while also leading negotiations with the US Food and Drug Administration and EU Health Authorities. He received his PhD in respiratory physiology and pharmacology from Liverpool John Moores University, UK.
Atriva Therapeutics
Nigel Horscroft
Atriva Therapeutics has appointed Nigel Horscroft as chief scientific officer. Horscroft is a scientist with over 20 years’ industry experience, recently serving as Atriva’s chief scientific officer. He previously served at MRM Health as chief scientific officer and spent over seven years at CureVac in a variety of roles, including as area head, molecular therapy and as vice president, development, RNArt. He also served at Pfizer.
Atriva Therapeutics
Stephan Witte
Atriva Therapeutics has appointed Stephan Witte as vice president clinical science and operations. Witte was head of clinical development and regulatory affairs at Inotrem and vice president, clinical trials at Breath Therapeutics. He is co-founder and managing director of Akesion GmbH. Witte also owns Helion Pharma, a drug development consultancy. He served for five years at Inotrem.
Medicines Discovery Catapult
Volker Hirsch
Medicines Discovery Catapult has appointed Volker Hirsch as its chief commercial officer. Hirsch brings a wealth of business leadership experience to the role, having spent over two decades in tech businesses in the UK, US, Germany where he drove corporate strategy, growth and expansion. Prior to this role, he was a partner at Amadeus Capital. He currently serves as a chairman for Advantage Creative on a part-time basis.
Centauri Therapeutics
David Roblin
Centauri Therapeutics has appointed David Roblin as chair of the board of directors. Roblin brings an extensive academic research background and has held senior leadership positions for over 20 years at Bayer and Pfizer. He is chair of scientific translation at the Francis Crick Institute, honorary Professor of Translational Medicine at St George’s Hospital and is also CEO of Relation Therapeutics.
ExeVir Bio
Jeanne Bolger
ExeVir has appointed Jeanne Bolger as chair to the board of directors. Bolger has over 35 years’ management experience across R&D, Commercial and Business Development and Venture Investments at Johnson & Johnson Innovation – JJDC and at GlaxoSmithKline. She is a venture partner at Seroba Life Sciences Venture Capital and serves on government advisory boards.
Closed Loop Medicine
David Van Sickle
Closed Loop Medicine has appointed David Van Sickle as non-executive director. van Sickle was the chief executive officer and co-founder of Propeller Health and in 2017, he served as a founding board member of the Digital Therapeutics (DTx) Alliance. In 2010, van Sickle was named a Champion of Change by the Obama administration for his work on technology and innovation.
Mainz Biomed
Douglas Rex
Mainz Biomed has appointed Douglas Rex to its Medical Advisory Board. Rex currently serves as Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and serves as the director of endoscopy at Indiana University Hospital in Indianapolis.
Ubiquigent
Sheelagh Frame
Ubiquigent has appointed Sheelagh Frame to its board of directors. Frame joined Ubiquigent in 2018 as head of biology, before being promoted to chief scientific officer in 2021. She has over 25 years’ experience in drug discovery, having served as programme manager and translational research team manager at Cyclacel, in oncology, inflammation, diabetes and rare diseases.
Makara Health
Louise Sharp
Makara Health has appointed Louise Sharp as chief executive officer. Sharp founded Makara Health in 2013 and has over 25 years’ industry experience. She co-founded two communications consultancies: Phase II International Communications, and Zaicom International Limited. She is also a founding partner of Ethos Pharmaceutical Ethics and Compliance.
Makara Health
Katie Bright
Makara Health has appointed Katie Bright as joint managing director. After completing an MA in Psychology and Physiology, and a MSc in Neuroscience at Oxford University, Bright has spent 20 years working within medical communications, including the past seven years at Makara Health in directorial roles and previously served at Spoonful of Sugar as a senior solutions director.
Makara Health
Helen Laurence
Makara Health has appointed Helen Laurence as its joint managing director. Laurence brings almost 20 years’ experience within the medical communications industry, having served at Makara Health for nearly seven years in directorial roles. Prior to this, she served as an account director for Gravitas Public Relations and as an associate director at Just:: Health Communications.
Resonant Group
Miranda Dini
Resonant Group has appointed Miranda Dini as chief operating officer. Dini will oversee Bedrock Healthcare Communications and Anthem Public Relations. She joins Resonant from her role as board director and global head of healthcare at AVENIR GLOBAL. She was also managing partner of AXON Europe and in March 2022, was recognised as one of Women in PR’s 45 Over 45.
Evoke London
Corrina Safeio
Evoke London has appointed Corrina Safeio as its group managing director. Safeio recently served as managing director, UK Evoke Mind+Matter. Prior to this, she worked for five years at Pegasus, serving as an associate director, head of planning and research, before moving onto her role as director of strategy and insights, and then as managing director. She also served as associate director for Havas Group from 2005 to 2012.
Evoke Mind+Matter UK
Lee Wales
Evoke Mind+Matter UK has appointed Lee Wales as deputy managing director. Wales began his time at the company as its client partnership director and before Evoke, served at Ashfield Digital & Creative for over nine years. He served as its digital strategy director, before taking the role of vice president, strategy, then moving onto managing director in 2018. He also served at AstraZeneca as a patient safety associate.
Evoke Mind+Matter UK
Holly Ford
Evoke Mind+Matter UK has appointed Holly Ford as head of consumer communications. Ford has been a part of the company for over four years, serving as associate director, consumer health and beauty, before taking on the role as head of consumer communications at Evoke Mind+Matter. She previously worked at Pegasus as a senior account director and also served at Hill+Knowlton Strategies as a senior account manager.
90Ten
Lynsey Stevenson
90Ten has appointed Lynsey Stevenson as senior scientific director. Stevenson brings a wealth of experience, recently serving at Ashfield MedComms, an Inizio Company, as its senior scientific strategy director. While there, she served as a principal medical writer and senior medical writer. She served at Complete Medical Communications for over five years, working her way up to the position of senior medical writer.
Bedrock Healthcare Communications
Alice Waterhouse
Bedrock Healthcare Communications has appointed Alice Waterhouse as associate scientific director. With over ten years’ medical communications experience, she recently served in the same position at LiNK Health Group and served as a senior medical writer for Chameleon Communications International. She also worked at Havas Lynx as a senior medical writer.
Bedrock Healthcare Communications
Laura Wilson
Bedrock Healthcare Communications has appointed Laura Wilson as client strategy director. With over a decade’s experience in medical communications across client services and business development, Wilson recently served at Nucleus Global as its commercial director, EU, and as associate commercial director. She also served at SciMentum as an account director.
Envision Pharma Group
Mel Formica
Envision Pharma Group has appointed Mel Formica as head of Envision Value and Access. Formica has a strong background as a life sciences leader and he currently serves as a member of the board at Pamanicor Health AG. He served as global head, value and development consulting at Evidera. He previously served as vice president, global market access at Takeda Pharmaceuticals.
POP Health Communications
Sabrina Gomersall
POP Health Communications has appointed Sabrina Gomersall as its founding director. Gomersall recently served at 90Ten for over four years, starting as director, PR, head of client services, before becoming the agency’s managing director, communications. Prior to her work at 90Ten, she served as a consultant for the Chandler Chicco Agency. She served as a director at WCG.